Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2025-12-25 @ 5:04 AM
NCT ID:
NCT03860818
Eligibility Criteria:
Inclusion Criteria:
* Veteran organ transplant recipients will be identified using International Classification of Diseases (ICD) 9/10 codes from the VA electronic health record (CPRS).
* Patients must have an active code stating they are a recipient of an organ transplant.
* The following codes will be utilized - ICD-9 codes:
* V42.0
* V42.1
* V42.6
* V42.7
* V42.83
* V42.84
* 996.81
* 996.82
* 996.83
* 996.84
* 996.86
* 52.80
OR
* oICD-10 codes:
* C80.2
* T86.1
* T86.10
* T86.11
* T86.12
* T86.13
* T86.19
* T86.2
* T86.20
* T86.21
* T86.22
* T86.23
* T86.290
* T86.298
* T86.3
* T86.30
* T86.31
* T86.32
* T86.33
* T86.39
* T86.4
* T86.40
* T86.41
* T86.42
* T86.43
* T86.49
* T86.810
* T86.811
* T86.812
* T86.818
* T86.819
* T86.9
* Z48.2
* Z48.21
* Z48.22
* Z48.23
* Z48.24
* Z48.280
* Z48.288
* Z48.298
* Z94.0
* Z94.1
* Z94.2
* Z94.3
* Z94.4
* Z94.83
AND
* Actively receiving at least one anti-rejection medication dispensed by the VA site.
* These medications include:
* tacrolimus
* cyclosporine
* azathioprine
* mycophenolate
* sirolimus
* everolimus
* belatacept
Exclusion Criteria:
* There are no exclusion criteria for patients in this study as recruitment is at the level of the VA site.
* All veterans meeting inclusion criteria will be monitored by the dashboard system and will be included in the outcomes assessment.
* Patients may enter or exit the study in a rolling manner, which will be accounted for during analyses.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT03860818
Study Brief:
Protocol Section:
NCT03860818